This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Brief Summary
The core objectives of this study are to assess the short-term and long-term efficacy of auricular acupoint pressure beans combined with electroacupuncture and estazolam in the treatment of cancer-caused insomnia. The study aims to accurately compare the differences between this combination therapy and standard Western medicine in improving sleep quality and effectively alleviating anxiety and depression. Additionally, it will meticulously observe the safety of the combined treatment and record the occurrence and potential causative factors of any adverse reactions.
Registry Overview
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Recruitment status
recruiting
Estimated enrollment
60 participants
Study completion date
December 1, 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations
1 countries · 1 sites
Trial Relationships
Click on a node to explore related trials.
Related Scientific Literature
Loading related publications...
Study Timeline
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
First Submitted
February 27, 2025
Actual (reported)
Study Start
March 1, 2025
Actual (reported)
First Posted
March 5, 2025
Actual (reported)
Primary Completion
March 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
The scale is a simple tool used for screening insomnia, consisting of 7 items designed to assess the nature and symptoms of sleep disturbances in the subjects.
Data will be collected at the end of the 0th, 4th, and 8th weeks of treatment and during follow-up (12th, 16th, and 20th weeks).
Secondary Outcomes (3)
Pittsburgh Sleep Quality Index(PSQI)
Data will be collected at the end of the 0th, 4th, and 8th weeks of treatment and during follow-up (12th, 16th, and 20th weeks).
Hamilton Anxiety Scale(HAMA)
Data will be collected at the end of the 0th, 4th, and 8th weeks of treatment and during follow-up (12th, 16th, and 20th weeks).
Hamilton Depression Rating Scale(HAMD)
Data will be collected at the end of the 0th, 4th, and 8th weeks of treatment and during follow-up (12th, 16th, and 20th weeks).
Study Arms (2)
Arm I (ONS group)
EXPERIMENTAL
Patients will receive estazolam with auricular pressure points and electroacupuncture treatment.
Interventions:In the experimental group, estazolam (oral estazolam 1-2 mg daily at bedtime) was combined with auricular pressure point therapy and electroacupuncture over an 8-week period.
Drug: estazolam 1-2 mgProcedure: Auricular pressure bean combined with electroacupuncture
Arm II (NS group)
ACTIVE COMPARATOR
Patients will follow the standard estazolam treatment program(oral estazolam 1-2 mg daily at bedtime for 8 weeks).
Electroacupuncture treatment will be performed on seven acupoints, including Baihui (GV20), Shenting (GV24), Yintang (GV29), Anmian (EX-HN22), Shenmen (HT7), Neiguan (PC6), and Sanyinjiao (SP6). Each session lasts for 30 minutes and is conducted twice a week.In addition, auricular point seed-pressing therapy will be applied to bilateral auricular points related to insomnia (Shenmen, Heart, and Sympathetic). Each auricular point will be pressed for 1 minute, three times a day. The total treatment course is eight weeks.
Eligibility Criteria
Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
You may qualify if:
Age 18 and above.
The diagnosis of a malignant solid tumor was confirmed by pathological examination.
Clinically diagnosed cancer-caused insomnia with insomnia symptoms lasting more than 1 month, more than 3 or more times per week.
An Insomnia Severity Index (ISI) score of 8 or higher and meets the criteria for insomnia disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.
No medications related to the treatment of insomnia have been used in the last 1 month.
No serious dysfunction of the heart, liver, kidneys or other vital organs.
Patients volunteered to participate in this study and signed an informed consent form.
You may not qualify if:
Irregular sleep-wake cycles in jobs with shift demands or due to inconsistent work schedules.
Inadequately treated for another sleep disorder (e.g., sleep disorder disorders such as sleep apnea obstruction syndrome, restless leg syndrome, etc.).
Received acupuncture or auricular pressure bean therapy within the past 3 months.
Estimated life expectancy is ≥3 months.
Have a history of severe allergies, especially to the drugs or treatments used in this study.
History of severe mental illness with a current episode.
History of substance abuse or alcohol dependence.
Contact the study team to confirm eligibility.
Heterocyclic Compounds
Combined Modality Therapy
Therapeutics
Acupuncture Therapy
Complementary Therapies
Electric Stimulation Therapy
Physical Therapy Modalities
Rehabilitation
Transcutaneous Electric Nerve Stimulation
Analgesia
Anesthesia and Analgesia
Anesthesia
Study Completion
December 1, 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 25, 2025
Record last verified: 2025-02
Source record
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.